Commercial Insight: Multiple Sclerosis - Next Generation Therapies Signal The Start Of A New Era

Introduction

Introduction

With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. Although growth will be stifled by biosimilars, these new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years (20092019).

Scope

*In-depth analysis of the current and future multiple sclerosis therapies across the US, Japan, France, Germany, Italy, Spain and the UK.

*Country-specific total brand sales forecasts for key products, biosimilars and pipeline agents across the seven major markets to 2019.

*Assessment of the commercial opportunities and threats present in the multiple sclerosis market, with analysis of trends in emerging markets.

*Evaluation of the strategies of leading players in the multiple sclerosis disease market.

Highlights

Datamonitor expects Novartis's Gilenia (fingolimod) to launch at the end of 2010 as a first-line therapy, while Merck Serono's oral cladribine is anticipated to launch at the start of 2011. These drugs offer improved efficacy and a less invasive method of administration than current treatments.

Datamonitor expects entry of biosimilar drugs from 2014. The Introduction of cost competition will force current market players to cease raising the price of their drugs above the norm; a strategy that has helped them to substantially increase revenues in recent years.

Novartis is set to usurp Biogen Idec and become the market leading player by the end of the forecast period in 2019. In addition to Gilenia and Extavia (interferon beta 1b), Novartis is developing two multiple sclerosis candidates; PI-230 (Phase I) and BAF312 (Phase II), illustrating its commitment to growing its presence in the marketplace

Reasons to Purchase

*Quantify the current and future size of the multiple sclerosis drug class market and understand the main commercial opportunities and threats

*Assess key marketed and pipeline drugs, including new oral agents, Acorda's Ampyra (dalfampridine) and GW Pharmaceuticals' Sativex (nabiximols).

*Understand the country-specific impact of key events in the multiple sclerosis market during the forecast period 2010 to 2019.

Table of Contents :

OVERVIEW 1

Catalyst 1

Summary 1

ABOUT DATAMONITOR HEALTHCARE 2

About the central nervous system pharmaceutical analysis team 2

EXECUTIVE SUMMARY 3

Strategic scoping and focus 3

Datamonitor insight into the multiple sclerosis market 3

Related reports 4

TABLE OF CONTENTS 5

1. MARKET DEFINITION 6

Market definition for this report 6

2. MARKET OVERVIEW 7

Seven major markets 7

Current market assessment 7

Notable historical growth in multiple sclerosis sales exceeds volume growth from 2005 to 2009 8

The interferons contributed over half of all sales in the multiple sclerosis disease-modifying market in 2009 10

Copaxone outstrips Avonex to become market leader 11

Approved Tysabri continues strong year-on-year growth 12

Future market assessment 13

Key multiple sclerosis brands will undergo strong competition 13

Market value will continue to grow until generic incursion in 2014 13

Pipeline oral disease modifiers will offset generic incursion 14

Opportunities and threats 17

Opportunities 1: efficacious treatment for progressive multiple sclerosis remains a key unmet need 17

Opportunities 2: identifying patients before symptoms emerge 19

Opportunities 3: development of biomarkers will lead to a earlier treatment approach 20

Opportunities 4: targeting symptomatic treatment opens up large patient population 21

For more information please visit :

http://www.aarkstore.com/reports/Commercial-Insight-Multiple-Sclerosis-Next-generation-therapies-signal-the-start-of-a-new-era-52714.html

by: Aarkstore Enterprise

POST COMMENT

Anti Aging Skincare Products For A Whole New You Solar water heater to the countryside "enterprise strength" to the countryside - solar, solar water heater - Solar Industry Ugg Become a Hit for the New Millennium Ecommerce and the new world currency The New Fitness Boots Keeping You Fit And Warm Taking The Decision To Look At New Kitchens Locating A Brand New Philadelphia Dentist Aarkstore Enterprise Concentrated Photovoltaic (pv) And Solar Photovoltaic Global Market (2009 - 20 Series have also added a new silver watch Open Plan New Kitchens Need a new carpet style? Aarkstore Enterprise Concentrated Photovoltaic (pv) And Solar Photovoltaic Global Market (2009 Why You Need A New Driveway